Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial

Enya Scanlon(Queen's University Belfast), Richard Turkington(Queen's University Belfast), Julie Turbitt(University of Aberdeen), Leena Elhussein(University of Oxford), Jaine K. Blayney(Queen's University Belfast), Russell Petty(Aberdeen Royal Infirmary), Stephen McQuaid(Queen's University Belfast), Z Miedzybrodzka(University of Aberdeen), Mark R. Middleton(University of Oxford), Ryan M. Byrne(Queen's University Belfast), Jacqueline A. James(Queen's University Belfast), Pradeep S. Virdee(University of Oxford), Adrian Lavery(Queen's University Belfast), Anne Thomas(Leicester Royal Infirmary), David Collinson(Lancaster University), Richard D. Kennedy(Queen's University Belfast), D. Paul Harkin(Almac (United Kingdom)), Leanne Stevenson(Queen's University Belfast), Mohammad Albraikat(Queen's University Belfast), B Mullan-Young(Queen's University Belfast), Damian McManus(Belfast Health and Social Care Trust), Cameron Kennedy(Queen's University Belfast), Stephanie G. Craig(Queen's University Belfast), Martin Eatock(Queen's University Belfast), Sandra Van Schaeybroeck(Queen's University Belfast)
ESMO Open
October 11, 2024
Cited by 0


Related Papers